What does ETIS PHARMA do?

ETIS PHARMA is a pharmacy in Pont-à-Celles. Private Limited, started on 7 September 2018, 1 establishment.

What is the address of ETIS PHARMA?

The registered office of ETIS PHARMA is located at Place du Marais(PAC) 2, 6230 Pont-à-Celles.

Is ETIS PHARMA still active?

Yes. According to the CBE (31 October 2026) ETIS PHARMA is active, legal situation “Normale toestand”, started on 7 September 2018.

Is ETIS PHARMA registered on Peppol?

Yes, ETIS PHARMA is registered on the Peppol network with ID 0208:0702914656.

What is the enterprise number of ETIS PHARMA?

The enterprise number of ETIS PHARMA is BE0702914656.

When was ETIS PHARMA founded?

ETIS PHARMA was founded on 7 September 2018.

Who are the directors of ETIS PHARMA?

According to the 2026 annual accounts, the directors of ETIS PHARMA are: Etienne EVRARD.

Is ETIS PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 September 2018; 5 annual accounts filed, latest fiscal year 2026; 1 directors known from the annual account.

How much profit did ETIS PHARMA make in 2026?

ETIS PHARMA posted a profit after taxes of € 21,250 in financial year 2026.

What is the revenue of ETIS PHARMA?

As a small company, ETIS PHARMA is not required to publish revenue in its annual accounts. In financial year 2026, its added value was € 259,449.

How much does an employee at ETIS PHARMA earn?

The average wage cost per full-time employee at ETIS PHARMA was € 50,200 in 2026: staff costs of € 175,864 for 3.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ETIS PHARMA have?

According to the 2026 annual accounts, ETIS PHARMA has 3.5 full-time equivalents (FTE).

ETIS PHARMA (Private Limited) - Pont-à-Celles

Dossier ETIS PHARMA, printed on 1 November 2026 from databakkes.be/en/0702914656/etis-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 57 % of short-term debt in 2026; threshold 65 %.

Financials

Financial year 2026

ETIS PHARMA from Pont-à-Celles, company number BE0702914656, closed financial year 2026 with a result of € 21,250 after tax. For that financial year ETIS PHARMA recorded a gross margin of € 259,449 and equity of € 18,611. Compared with financial year 2025, the result moved from € 2,116 to € 21,250. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 7, 2026.

What it is worth Healthy

€ 18,611

▼ 10% vs 2025

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 21,250

▲ € 19,134 vs 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 135,878

▲ 52% vs 2025

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 23,400 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2026

Full-time equivalents

3.5

▲ 0.4 vs 2025

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 175,864

▲ 12% vs 2025

€ 50,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 14,268

▼ 40% vs 2025

Of which on lease € 727.

Debts at end 2026

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 250,268

▼ 14% vs 2025

€ 38,574 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 210,903

▲ 4% vs 2025

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 32,199

▲ 31% vs 2025

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	2026	Change 2025 → 2026
Gross margin	€ 236,870 Gross margin 2023: € 236,870 First fiscal year in the series	€ 241,102 Gross margin 2024: € 241,102 ▲ 2% vs 2023 (€ 236,870) Favourable step	€ 217,947 Gross margin 2025: € 217,947 ▼ 10% vs 2024 (€ 241,102) Unfavourable step	€ 259,449 Gross margin 2026: € 259,449 ▲ 19% vs 2025 (€ 217,947) Favourable step	▲ 19%
Profit after taxes	€ 47,046 Profit after taxes 2023: € 47,046 First fiscal year in the series	€ 38,733 Profit after taxes 2024: € 38,733 ▼ 18% vs 2023 (€ 47,046) Unfavourable step	€ 2,116 Profit after taxes 2025: € 2,116 ▼ 95% vs 2024 (€ 38,733) Unfavourable step	€ 21,250 Profit after taxes 2026: € 21,250 ▲ € 19,134 vs 2025 (€ 2,116) Favourable step	▲ € 19,134
Equity	€ 191,879 Equity 2023: € 191,879 First fiscal year in the series	€ 143,946 Equity 2024: € 143,946 ▼ 25% vs 2023 (€ 191,879) Unfavourable step	€ 20,761 Equity 2025: € 20,761 ▼ 86% vs 2024 (€ 143,946) Unfavourable step	€ 18,611 Equity 2026: € 18,611 ▼ 10% vs 2025 (€ 20,761) Unfavourable step	▼ 10%
Total debts	€ 567,721 Total debts 2023: € 567,721 First fiscal year in the series	€ 527,283 Total debts 2024: € 527,283 ▼ 7% vs 2023 (€ 567,721) Favourable step	€ 596,886 Total debts 2025: € 596,886 ▲ 13% vs 2024 (€ 527,283) Unfavourable step	€ 580,755 Total debts 2026: € 580,755 ▼ 3% vs 2025 (€ 596,886) Favourable step	▼ 3%
Cash	€ 147,056 Cash 2023: € 147,056 First fiscal year in the series	€ 120,342 Cash 2024: € 120,342 ▼ 18% vs 2023 (€ 147,056) Unfavourable step	€ 89,440 Cash 2025: € 89,440 ▼ 26% vs 2024 (€ 120,342) Unfavourable step	€ 135,878 Cash 2026: € 135,878 ▲ 52% vs 2025 (€ 89,440) Favourable step	▲ 52%
Land & buildings	€ 265,513 Land & buildings 2023: € 265,513 First fiscal year in the series	€ 250,626 Land & buildings 2024: € 250,626 ▼ 6% vs 2023 (€ 265,513) Unchanged	€ 237,684 Land & buildings 2025: € 237,684 ▼ 5% vs 2024 (€ 250,626) Unchanged	€ 219,944 Land & buildings 2026: € 219,944 ▼ 7% vs 2025 (€ 237,684) Unchanged	▼ 7%
Retained profit	€ 173,279 Retained profit 2023: € 173,279 First fiscal year in the series	€ 125,346 Retained profit 2024: € 125,346 ▼ 28% vs 2023 (€ 173,279) Unfavourable step	€ 2,161 Retained profit 2025: € 2,161 ▼ 98% vs 2024 (€ 125,346) Unfavourable step	€ 11 Retained profit 2026: € 11 ▼ € 2,151 vs 2025 (€ 2,161) Unfavourable step	▼ € 2,151
Dividend	€ 0 Dividend 2023: € 0 First fiscal year in the series	€ 86,667 Dividend 2024: € 86,667 Unchanged (€ 0) Unchanged	€ 125,300 Dividend 2025: € 125,300 ▲ 45% vs 2024 (€ 86,667) Unchanged	€ 23,400 Dividend 2026: € 23,400 ▼ 81% vs 2025 (€ 125,300) Unchanged	▼ 81%
Bank debt	€ 369,905 Bank debt 2023: € 369,905 First fiscal year in the series	€ 335,509 Bank debt 2024: € 335,509 ▼ 9% vs 2023 (€ 369,905) Favourable step	€ 291,257 Bank debt 2025: € 291,257 ▼ 13% vs 2024 (€ 335,509) Favourable step	€ 250,268 Bank debt 2026: € 250,268 ▼ 14% vs 2025 (€ 291,257) Favourable step	▼ 14%
Balance sheet total	€ 759,600 Balance sheet total 2023: € 759,600 First fiscal year in the series	€ 671,229 Balance sheet total 2024: € 671,229 ▼ 12% vs 2023 (€ 759,600) Unchanged	€ 617,647 Balance sheet total 2025: € 617,647 ▼ 8% vs 2024 (€ 671,229) Unchanged	€ 599,365 Balance sheet total 2026: € 599,365 ▼ 3% vs 2025 (€ 617,647) Unchanged	▼ 3%
Employees (FTE)	2.3 Employees (FTE) 2023: 2.3 First fiscal year in the series	2.6 Employees (FTE) 2024: 2.6 ▲ 0.3 vs 2023 (2.3) Unchanged	3.1 Employees (FTE) 2025: 3.1 ▲ 0.5 vs 2024 (2.6) Unchanged	3.5 Employees (FTE) 2026: 3.5 ▲ 0.4 vs 2025 (3.1) Unchanged	▲ 0.4

Key figures of ETIS PHARMA, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 August 2027.

What happened to ETIS PHARMA?

What happened at ETIS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

May 7, 2026 New annual accounts for financial year 2026: profit of € 21,250 (▲ € 19,134 vs 2025). Source: NBB ↗
Sep 13, 2018 New establishment in Pont-à-Celles. KBO
Sep 7, 2018 Start of the company according to the CBE. KBO

In short

From € 47,046 profit in 2023 to € 21,250 profit in 2026.

Paid € 29,071 in corporate taxes since 2023.

Best year ever: 2023, with € 47,046 profit.

On average € 74,100 of value added per employee in 2026.

Original PDFs at the National Bank ↗

Management

Etienne EVRARD

ETIS PHARMA

Behind ETIS PHARMA is Etienne EVRARD.

Directors

According to the 2026 annual accounts

Etienne EVRARD

Administrator-manager

Establishments

Establishment units

Physical locations of this company

Registered office

Place du Marais(PAC) 2

6230 Pont-à-Celles

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0702.914.656
VAT number: BE 0702.914.656
Registered office: Place du Marais(PAC) 2, 6230 Pont-à-Celles
Names & denominations: ETIS PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 7 September 2018
Peppol: Active · Active since 6 Aug 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗